Opiant Pharmaceuticals Inc (OPNT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Opiant Pharmaceuticals Inc (OPNT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9841
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obese patients with binge eating disorder (BED), and for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc (OPNT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Opiant Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 13
Opiant Pharma and Titan Pharma Enter into Agreement 14
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 15
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 16
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 17
Lightlake Therapeutics To Enter Into Co-Development Agreement With King’s College London 18
Licensing Agreements 19
Consort Medical Enter into Development Agreement with Opiant Pharma 19
Opiant Pharma Enters into Licensing Agreement with Aegis Therapeutics 20
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 22
Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 23
Equity Offering 24
Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 24
Opiant Pharma Raises USD12 Million in Public Offering of Shares 26
Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 27
Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 28
Asset Transactions 29
Opiant Pharma Enters into Agreement with SWK for NARCAN Nasal Spray 29
Opiant Pharmaceuticals Inc – Key Competitors 30
Opiant Pharmaceuticals Inc – Key Employees 31
Opiant Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 07, 2018: Opiant Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 33
Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 35
May 08, 2018: Opiant Pharmaceuticals Announces First Quarter 2018 Financial Results 37
Mar 07, 2018: Opiant Pharmaceuticals Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update 38
Dec 04, 2017: Opiant Pharmaceuticals Reports Fiscal First Quarter 2018 Financial Results 39
Oct 13, 2017: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 40
Jun 15, 2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 42
Mar 16, 2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update 44
Corporate Communications 45
Oct 29, 2018: Opiant Pharmaceuticals names Craig Collard to Board of Directors 45
Jun 12, 2018: Opiant Pharmaceuticals Names Richard Daly As Board Director 46
Sep 05, 2017: Opiant Pharmaceuticals Announces Appointment of David O’Toole as Chief Financial Officer 47
Aug 28, 2017: Opiant Pharmaceuticals Announces Listing on the Nasdaq Capital Market 48
Feb 06, 2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer 49
Product News 50
02/28/2017: Opiant Pharmaceuticals Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder 50
Clinical Trials 51
Feb 12, 2018: Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose 51
Dec 18, 2017: Opiant Pharma Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine 52
Jul 19, 2017: Opiant Pharmaceuticals Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder 53
Mar 20, 2017: Opiant Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Opiant Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 13
Opiant Pharma and Titan Pharma Enter into Agreement 14
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 15
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 16
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 17
Lightlake Therapeutics To Enter Into Co-Development Agreement With King’s College London 18
Consort Medical Enter into Development Agreement with Opiant Pharma 19
Opiant Pharma Enters into Licensing Agreement with Aegis Therapeutics 20
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 22
Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 23
Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 24
Opiant Pharma Raises USD12 Million in Public Offering of Shares 26
Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 27
Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 28
Opiant Pharma Enters into Agreement with SWK for NARCAN Nasal Spray 29
Opiant Pharmaceuticals Inc, Key Competitors 30
Opiant Pharmaceuticals Inc, Key Employees 31
Opiant Pharmaceuticals Inc, Subsidiaries 32

List of Figures
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Opiant Pharmaceuticals Inc (OPNT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CNOOC Ltd (883):石油・ガス:M&Aディール及び事業提携情報
    Summary CNOOC Ltd (CNOOC) is an upstream oil and gas company. It carries out exploration, development, production and sale of crude oil and natural gas. The company has operations in Bohai, Western South China Sea, Eastern South China Sea and East China Sea in offshore China. It operates either inde …
  • Qingdao Haier Co., Ltd. (600690):企業の財務・戦略的SWOT分析
    Qingdao Haier Co., Ltd. (600690) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ascena Retail Group Inc:企業の戦略的SWOT分析
    Ascena Retail Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Danaher Corporation:企業の戦略・SWOT・財務情報
    Danaher Corporation - Strategy, SWOT and Corporate Finance Report Summary Danaher Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Swedbank AB:企業のM&A・事業提携・投資動向
    Swedbank AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Swedbank AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Navistar International Corp (NAV):企業の財務・戦略的SWOT分析
    Navistar International Corp (NAV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Australian Pharmaceutical Industries Ltd (API):企業の財務・戦略的SWOT分析
    Australian Pharmaceutical Industries Ltd (API) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Agile Therapeutics Inc (AGRX):企業の財務・戦略的SWOT分析
    Summary Agile Therapeutics Inc (Agile) is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol and progestin-only birth control patch. Its p …
  • Safe Orthopaedics SA (SAFOR)-医療機器分野:企業M&A・提携分析
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical equipment company that manufactures and markets minimally invasive devices for spinal surgery. The company’s product portfolio includes implants and surgical instruments. It offers modular cervical cages, percutaneous auto-correction screws …
  • Biognosys AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Biognosys AG (Biognosys) is a proteomics company which offers tools and services for highly multiplexed protein quantification. Its products portfolio includes calibration kits for reproducible mass spectrometry proteomics, and prediction of peptide retention; software support for multiple a …
  • Misen Energy AB (MISE):企業の財務・戦略的SWOT分析
    Summary Misen Energy AB (Misen), formerly Svenska Capital Oil AB is an oil and gas company that provides pipeline services. The company offers production of gas and oil fields by implementation of large-scale investment programs and introduction of modern western knowhow and technology. It offers de …
  • Sigma-Tau HealthScience USA, Inc:戦略・SWOT・企業財務分析
    Sigma-Tau HealthScience USA, Inc - Strategy, SWOT and Corporate Finance Report Summary Sigma-Tau HealthScience USA, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • RTI Surgical Inc (RTIX)-医療機器分野:企業M&A・提携分析
    Summary RTI Surgical Inc (RTI), formerly RTI Biologics Inc is a surgical implant company that offers biologic, metal and synthetic implants. The company’s products include spine implants, surgical specialties, sports medicine implants, cardiothoracic and orthobiologics. It offers spine implants such …
  • Delta Air Lines, Inc.:企業のM&A・事業提携・投資動向
    Delta Air Lines, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Delta Air Lines, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Peak Resources Ltd. (PEK):企業の財務・戦略的SWOT分析
    Peak Resources Ltd. (PEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • AIMM Therapeutics BV-製薬・医療分野:企業M&A・提携分析
    Summary AIMM Therapeutics BV (AIMM Therapeutics) is a biotechnology company that develops progressive approach to the discovery of therapeutic antibodies for the treatment of cancer and infectious diseases. The company offers research programs for prevention and treatment of diseases with medical ne …
  • Iroko Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Iroko Pharmaceuticals LLC (Iroko) is a specialty pharmaceutical company that develops and commercializes pharmaceutical products. The company’s products comprise low dose Nonsteroidal anti-inflammatory drugs such as meloxicam, indomethacin, and diclofenac that are in various stages of noncli …
  • Virginia Electric and Power Company:発電所・企業SWOT分析
    Virginia Electric and Power Company – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Vascular Biogenics Ltd (VBLT):製薬・医療:M&Aディール及び事業提携情報
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …
  • Staples, Inc.:企業の戦略・SWOT・財務情報
    Staples, Inc. - Strategy, SWOT and Corporate Finance Report Summary Staples, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆